Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease.
Lika A, Andrinopoulou ER, van der Beek NAME, Rizopoulos D, van der Ploeg AT, Kruijshaar ME
European journal of neurology, 2024 Feb 20
Abstract
Pompe disease is a rare, inheritable, progressive metabolic myopathy. This study aimed to estimate the minimal clinically important difference (MCID) for an improvement in forced vital capacity in the upright seated position (FVC ) and the 6-min walk test (6MWT) after a year of treatment with enzyme replacement therapy.